Novel Biologics in the Treatment of Colorectal Cancer
Current Therapies
5-Fluorouracil: History
Concept of “All-3-Drugs” - Update 2005
NOVEL MOLECULAR TARGETS 2006
Functions of Cell Surface Receptors
AN INTERESTING DILEMMA
THE TREE TRIAL (2 cohorts) comparing oxaliplatin schedules
TREE-1 and TREE-2: Treatment Schema
TREE-1 vs. TREE-2: Demographics
TREE-1: 5-FU/Capecitabine Dose Reductions
TREE-1 vs. TREE-2 Comparative Grade 3/4 toxicities –First 12 weeks of treatment
TREE-1 vs. TREE-2 Comparative Grade 3/4 toxicities -Overall
TREE-2: Grade 3/4Toxicities during the First 12 Weeks of Rx
TREE-2: Absolute Number of Patients with Specific Treatment-related Toxicities
TREE-2: Overall Incidence of Grade 3/4Toxicities
TREE-1 vs. TREE-2 Comparative Response Rate
TREE-1 vs. TREE-2 Comparative Analysis
All TKIs Are Not the Same
All TKIs Are Not the Same
Small Molecule Inhibitors
PTK787/ ZK 225846 (Vatalanib)
Phase III Trial of Vatalanib in First-Line MCRC (CONFIRM-1)
Sorafenib (BAY 43-9006)
Randomized Discontinuation Study – Treatment Plan
Tumor Size Changes After 12 Weeks of Treatment as Measured by Radiographic Measurements
Median Progression-Free Survival for Patients with Renal Cell Cancer Randomized to Placebo or Sorafenib
AZD2171 Clinical Data
Changes in DCE-MRI correlated with exposure to AZD2171
VEGF Trap (AVE0005)
VEGF Trap Phase I experience
VEGF Trap (AVE0005) Conclusion
Properties Cetuximab/IMC-C225
Properties Cetuximab/IMC-C225
Cetuximab ± Irinotecan in CRC
Combination Antibody Therapy MCRC NCI 5844 (“BOND-2”)
Efficacy Comparison (Historical Controls)
CALGB/SWOG Intergroup Trial 80405
PACCE Trial*
Strategies for future developments
CONCLUSIONS
CONCLUSIONS
